Subscribe to Newsletter
Outside the Lab Screening and monitoring

Seizing an Opportunity

“Amid high-priority efforts to eliminate hepatitis as a major public health threat, diagnostics must play a crucial role. With the boon of additional molecular testing capacity built during the pandemic, many clinical laboratories now have the chance to scale up their hepatitis screening to contribute to these efforts – a rare and hard-won opportunity that could have significant benefits for global health.”

- Erica Frew is Product Manager at Asuragen, a Bio-Techne brand, where she specializes in molecular controls for clinical tests.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Erica Frew

Product manager at Asuragen, a Bio-Techne brand, where she specializes in molecular controls for clinical tests. She is based in the Boston area, Massachusetts, US.

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register